Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jun;194(6):e63533.
doi: 10.1002/ajmg.a.63533. Epub 2024 Jan 17.

Metabolic and other morbid complications in congenital generalized lipodystrophy type 4

Affiliations

Metabolic and other morbid complications in congenital generalized lipodystrophy type 4

Gulcin Akinci et al. Am J Med Genet A. 2024 Jun.

Abstract

Morbidity and mortality rates in patients with autosomal recessive, congenital generalized lipodystrophy type 4 (CGL4), an ultra-rare disorder, remain unclear. We report on 30 females and 16 males from 10 countries with biallelic null variants in CAVIN1 gene (mean age, 12 years; range, 2 months to 41 years). Hypertriglyceridemia was seen in 79% (34/43), hepatic steatosis in 82% (27/33) but diabetes mellitus in only 21% (8/44). Myopathy with elevated serum creatine kinase levels (346-3325 IU/L) affected all of them (38/38). 39% had scoliosis (10/26) and 57% had atlantoaxial instability (8/14). Cardiac arrhythmias were detected in 57% (20/35) and 46% had ventricular tachycardia (16/35). Congenital pyloric stenosis was diagnosed in 39% (18/46), 9 had esophageal dysmotility and 19 had intestinal dysmotility. Four patients suffered from intestinal perforations. Seven patients died at mean age of 17 years (range: 2 months to 39 years). The cause of death in four patients was cardiac arrhythmia and sudden death, while others died of prematurity, gastrointestinal perforation, and infected foot ulcers leading to sepsis. Our study highlights high prevalence of myopathy, metabolic abnormalities, cardiac, and gastrointestinal problems in patients with CGL4. CGL4 patients are at high risk of early death mainly caused by cardiac arrhythmias.

Keywords: CAVIN1; congenital generalized lipodystrophy; gastrointestinal disease; metabolic abnormalities; myopathy; ventricular tachycardia.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest

BA run projects for and/or served as a consultant, board member, steering committee member, and/or speaker to Alnylam, Amryt, Regeneron, ThirdRock Ventures, Astra Zeneca, Novonordisk, Boehringer Ingelheim, Sanofi, Bilim Ilac, ARIS, and Servier. AG consults for Amryt Pharma plc, Regeneron, Kyttaro Limited, Third Rock Ventures, and has received grant support from Amryt Pharma plc, Regeneron, Quintiles, Akcea Pharmaceuticals, and Intercept Pharmaceuticals. AG is a co-holder of patents for use of leptin for treating human lipoatrophy and method of determining predisposition to said treatment but receives no financial benefit. RJB reports research support from Amryt Pharmaceuticals and Regeneron Pharmaceuticals. EAO reports the following conflicts: Grant support: Aegerion Pharmaceuticals (now Amryt Pharmaceuticals), Ionis Pharmaceuticals, Akcea Therapeutics, Gemphire Therapeutics, GI Dynamics (current), AstraZeneca (past two years). Consultant or Advisor: AstraZeneca, Thera Therapeutics, and BMS (past), Aegerion Pharmaceuticals (now Amryt Pharmaceuticals), Regeneron Pharmaceuticals (current). Drug support: Aegerion Pharmaceuticals (now Amryt Pharmaceuticals), Akcea Therapeutics, Rhythm Pharmaceuticals (all current). Other support: Aegerion Pharmaceuticals (now Amryt Pharmaceuticals), Regeneron Pharmaceuticals (current). TS consulted for Amryt and received grant support for an investigator-initiated trial from Aegerion Pharmaceuticals (now Amryt Pharmaceuticals). MB received an Honorarium as a speaker for Amryt Pharmaceuticals. CK received fees for Lecture and Advisory Board Membership from Amryt Pharmaceuticals. MW has served as consultant for Alnylam, Amryt, LG Chem, Regeneron, ThirdRock Ventures and is PI in clinical studies sponsored by Amryt. NP served as board member and consultant for Amryt Pharmaceutical and Ionis. ES attended advisory board/steering committee meetings organized by Amryt Pharmaceuticals and Regeneron Pharmaceuticals, Inc. Other authors report no conflicts of interest.

Figures

Figure 1:
Figure 1:. Phenotypic features and metabolic and organ complications in CGL4.
A. Patient pictures showing generalized fat loss; patient 7 (panel I) and patient 8 (panel II). B. Whole-body MRI (T1-weighted) demonstrating near total fat loss in a patient with CGL4 (patient 1; MRI performed at age of 16 years). Bone marrow fat is preserved along with orbital fat. Scalp fat is lost. Palms and soles show no significant fat signal. Reduced amounts of supraclavicular fat can be visualized. (I), whole body, coronal T1-weighted imaging; (II), whole body, coronal T2-weighted fat suppressed imaging; (III), orbital and scalp, axial T1-weighted imaging; (IV), shoulders, axial T1-weighted imaging; (V), breasts, axial T1-weighted imaging; (VI), visceral and retroperitoneal, axial T1-weighted imaging; (VII-VIII), external genital region and palms, axial T1-weighted imaging; (IX-XI), limbs, axial T1-weighted imaging. C. Kaplan Meier curves showing time to diabetes (panel I). A liver biopsy specimen (panel II) showing early changes of hepatic steatosis at age 1 in a patient with CGL4 (patient 3). Mild swelling of parenchymal cells. and macro- and microvesicular lipid depositions are shown (H&EX400). Kaplan Meier curves showing time to cardiac disease (panel III) and survival (panel IV) D. ECG showing Wolff-Parkinson-White syndrome (panel I) and an episode of ventricular tachycardia (panel II) in patient 8, and non-sustained polymorphic ventricular tachycardia (panel III) during treadmill exercise test in patient 2. E. Axial computerized tomography (CT) image showing air-fluid level due to intestinal perforation (panel I). Histopathology shows muscularis propria hypertrophy along with loss of orientation of circular and longitudinal layers of muscularis propria (panel II). Patient 1 had complaints of abdominal distention and pain that usually happened after meals (a feeling of fullness and early satiety and episodes of constipation and diarrhea when she first presented). Her symptoms were first treated with prokinetic agents, but no significant relief was observed. A small bowel follow-through study using barium showed slow transit time. At age 21, she presented with severe abdominal pain and tenderness. A CT showed colonic perforation and she underwent a colonic resection with colostomy. She did not have recurrent perforations but still lives with a colostomy bag.
Figure 2:
Figure 2:. Pathogenic variants reported in the CAVIN1 gene.
A. Schematic drawing of the CAVIN1 gene and the pathogenic variants. Black rectangles are the coding regions of the exons and white rectangles indicate the non-coding regions. Solid line between the exons indicates the intronic region. CAVIN1 constitutes only two exons shown with numbers. The 5’ and 3’ ends are shown. Schematic is not drawn to scale. The numbering is as per the coding DNA. B. Schematic of the CAVIN1 protein and the pathogenic variants. CAVIN1 constitutes 390 amino acids. Modified from Nassar. International Review of Cell and Molecular Biology, Volume 320, 2015. The disordered regions are shown in light blue and helical regions in gray. The PEST (proline–glutamic acid–serine–threonine) domains are shown in black, and the Leucine zipper domains in green. The nuclear localization signals are shown in dark blue. Variants above the schematics are previously reported and those below are novel. Variants in orange color are reported in the paper and those in black color are not reported in the paper.

References

    1. Acar N, Acar T, Suataman B, Ekinci N, & Tatar F (2022). Coexistence of Colon Perforation and Congenital Lipodystrophy. J Coll Physicians Surg Pak, 32(9), 1222–1224. 10.29271/jcpsp.2022.09.1222 - DOI - PubMed
    1. Adiyaman SC, J VS, De Laffolie J, Hahn A, Siebert R, Wabitsch M, & Kamrath C (2022). Congenital generalized lipodystrophy type 4 due to a novel PTRF/CAVIN1 pathogenic variant in a child: effects of metreleptin substitution. J Pediatr Endocrinol Metab, 35(7), 946–952. 10.1515/jpem-2022-0022 - DOI - PubMed
    1. Agarwal AK, Arioglu E, De Almeida S, Akkoc N, Taylor SI, Bowcock AM, . . . Garg A (2002). AGPAT2 is mutated in congenital generalized lipodystrophy linked to chromosome 9q34. Nat Genet, 31(1), 21–23. 10.1038/ng880ng880 [pii] - DOI - PubMed
    1. Akinci B, Oral EA, Neidert A, Rus D, Cheng WY, Thompson-Leduc P, . . . Brown RJ (2019). Comorbidities and Survival in Patients With Lipodystrophy: An International Chart Review Study. J Clin Endocrinol Metab, 104(11), 5120–5135. 10.1210/jc.2018-02730 - DOI - PMC - PubMed
    1. Akinci B, Sahinoz M, & Oral E (2000). Lipodystrophy Syndromes: Presentation and Treatment. In Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dhatariya K, Dungan K, Hershman JM, Hofland J, Kalra S, Kaltsas G, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrere B, Levy M, McGee EA, McLachlan R, Morley JE, New M, Purnell J, Sahay R, Singer F, Sperling MA, Stratakis CA, Trence DL, & Wilson DP (Eds.), Endotext. https://www.ncbi.nlm.nih.gov/pubmed/29989768 - PubMed

Publication types

LinkOut - more resources